Leerink Partners Reiterates Outperform Rating on BridgeBio Pharma (BBIO) after data presentation: "risk/reward skewed to the upside"
Leerink Partners analyst Mani Foroohar reiterated an Outperform rating and $98.00 price target on BridgeBio Pharma (NASDAQ: BBIO)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)